Side effects associated with homogenous and heterogenous doses of Oxford-AstraZeneca vaccine among adults in Bangladesh: an observational study.

Side effects associated with homogenous and heterogenous doses of Oxford-AstraZeneca vaccine among adults in Bangladesh: an observational study.

Publication date: Oct 11, 2024

Assessment of side effects associated with COVID-19 vaccination is required to monitor safety issues and acceptance of vaccines in the long term. We found a significant knowledge gap in the safety profile of COVID-19 vaccines in Bangladesh. We enrolled 1805 vaccine recipients from May 5, 2021, to April 4, 2023. Kruskal-Wallis test and χ2 test were performed. Multivariable logistic regression was also performed. First, second and third doses were administered among 1805, 1341, and 923 participants, respectively. Oxford-AstraZeneca (2946 doses) was the highest administered followed by Sinopharm BIBP (551 doses), Sinovac (214 doses), Pfizer-BioNTech (198 doses), and Moderna (160 doses), respectively. Pain at the injection site (80-90%, 3200-3600), swelling (85%, 3458), redness (78%, 3168), and heaviness in hand (65%, 2645) were the most common local effects, and fever (85%, 3458), headache (82%, 3336), myalgia (70%, 2848), chills (67%, 2726), muscle pain (60%, 2441) were the most prevalent systemic side effects reported within 48 h of vaccination. Thrombosis was only reported among the Oxford-AstraZeneca recipients (3. 5-5. 7%). Both local and systemic effects were significantly associated with the Oxford-AstraZeneca (p-value 

Open Access PDF

Concepts Keywords
Bangladesh Adolescent
Headache Adult
Vaccination Bangladesh
Bangladesh
ChAdOx1 nCoV-19
ChAdOx1 nCoV-19
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Female
Headache
Heterogenous
Humans
Long-term
Male
Middle Aged
SARS-CoV-2
Vaccination
Young Adult

Semantics

Type Source Name
disease MESH COVID-19
disease IDO site
disease MESH Thrombosis
disease MESH Chronic urticaria
disease MESH psoriasis
drug DRUGBANK Coenzyme M
disease MESH emergency
disease MESH hypertension
disease MESH asthma
pathway KEGG Asthma
disease MESH COPD
disease MESH autoimmunity
disease MESH obesity
disease MESH infection
disease IDO history
disease MESH urticaria
disease MESH inflammation
disease MESH complications
disease MESH restlessness
disease MESH allergic reactions
disease MESH back pain
disease IDO host
disease MESH autoimmune diseases
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH long COVID
disease MESH death
disease MESH morbidity
disease MESH comorbidity
disease MESH Influenza
disease MESH Anemia
disease MESH Bronchitis
disease IDO country
disease MESH thrombocytopenia
disease IDO symptom
disease MESH infectious diseases
disease IDO blood
disease MESH breakthrough infections
drug DRUGBANK Bismuth subgallate
disease MESH venous thromboembolism
disease MESH bleeding
disease MESH Thromboembolism
disease MESH cardiovascular diseases
pathway REACTOME Reproduction

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *